A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab
O'Connor, Owen A., Deng, Changchun, Amengual, Jennifer Effie, Khalil, Mazen Y., Schreeder, Marshall T., Mahadevan, Daruka, Nikolinakos, Petros, Sawas, Ahmed, Zain, Jasmine M., Patterson, Molly, Moon, Amber, Pauli, Emily K., Cutter, Kathy, Mackenzie, Michelle Ann, Brotherton, Marnie, Hodgson, Jamie, Cooper, Christen N, Sportelli, Peter, Miskin, Hari P., Farber, Charles Michael
Published in Journal of clinical oncology (20.05.2014)
Published in Journal of clinical oncology (20.05.2014)
Get full text
Journal Article